Literature DB >> 18820857

[The use of erythropoiesis-stimulating proteins in anemic patients with malignant diseases].

Heinz Ludwig, Thomas Auberger, Otto Ch Burghuber, Michael Gnant, Georg Hopfinger, Ulrich Jäger, Felix Keil, Gabriela Kornek, Werner Linkesch, Edgar Petru, Robert Pirker, Elisabeth Pittermann, Alexander Reinthaller, Hellmut Samonigg, Günther Steger, Felix Stockenhuber, Michael Studnicka, Günter Weiss, Christoph Zielinski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18820857     DOI： 10.1007/s00508-008-1007-4

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  30 in total

1.  Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors.

Authors:  A C Amato; M Pescatori
Journal:  Dis Colon Rectum       Date:  1998-05       Impact factor: 4.585

2.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Authors:  Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

Review 3.  EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

Authors:  C Bokemeyer; M S Aapro; A Courdi; J Foubert; H Link; A Osterborg; L Repetto; P Soubeyran
Journal:  Eur J Cancer       Date:  2006-12-19       Impact factor: 9.162

4.  Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

Authors:  Anders Osterborg; Y Brandberg; V Molostova; G Iosava; K Abdulkadyrov; M Hedenus; D Messinger
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

5.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors:  T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

6.  A randomized controlled study of iron supplementation in patients treated with erythropoietin.

Authors:  I C Macdougall; B Tucker; J Thompson; C R Tomson; L R Baker; A E Raine
Journal:  Kidney Int       Date:  1996-11       Impact factor: 10.612

7.  Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

Authors:  James R Wright; Yee C Ung; Jim A Julian; Kathleen I Pritchard; Timothy J Whelan; Column Smith; Barbara Szechtman; Wilson Roa; Liam Mulroy; Leona Rudinskas; Bruno Gagnon; Gord S Okawara; Mark N Levine
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

8.  Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

Authors:  Thomas E Witzig; Peter T Silberstein; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; James A Mailliard; Kendrith M Rowland; Steven R Alberts; James E Krook; Ralph Levitt; Roscoe F Morton
Journal:  J Clin Oncol       Date:  2004-09-27       Impact factor: 44.544

9.  Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

Authors:  Jose Chang; Felix Couture; Scott Young; Kara-Lee McWatters; Catherine Y Lau
Journal:  J Clin Oncol       Date:  2004-09-27       Impact factor: 44.544

10.  Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.

Authors:  M Cazzola; D Messinger; V Battistel; D Bron; R Cimino; L Enller-Ziegler; U Essers; R Greil; A Grossi; G Jäger; A LeMevel; A Najman; V Silingardi; M Spriano; A van Hoof; B Ehmer
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.